Serotonin Reuptake Inhibitor and Bleeding Risk: PART 2: Gastrointestinal (GI) Bleeding, Malignancy, Pregnancy, and Surgical Considerations.
| Autor: | Robbins-Welty, Gregg A., Tuck, Andrew N., Marchant, Dale, Gleason, Andrew, Key, Richard Garrett, Lubrano di Ciccone, Barbara B., Chopra, Deepti A., Mojtahedzadeh, Mona, Fonseca, Fiona, Lokko Amonoo, Hermioni, DeSimone, Andrea, McFarland, Daniel |
|---|---|
| Předmět: |
HEMORRHAGE risk factors
GASTROINTESTINAL disease prevention SURGICAL blood loss PERIOPERATIVE care HORMONE therapy SEROTONIN uptake inhibitors GASTROINTESTINAL hemorrhage CONTINUING education units RISK assessment ALCOHOL drinking MENTAL depression DRUG interactions PEPTIC ulcer DISEASE risk factors DISEASE complications PREGNANCY |
| Zdroj: | Psychiatric Times; Oct2023, Vol. 40 Issue 10, p42-45, 4p |
| Abstrakt: | The article describes bleeding risk with serotonin reuptake inhibitors (SRI) in gastrointestinal (GI) bleeds, surgical/perioperative conditions, malignancy, and pregnancy, and in patients treated with hormonal therapies. Topics covered include broader recommendations for SRI use, the possible coprescription of an acid-suppressing agent with an SRI, and the insufficiency of data to consider SRI dose adjustment in certain patients. Also noted is the consideration of SRI withdrawal symptoms. |
| Databáze: | Complementary Index |
| Externí odkaz: |
|